Myriad to Launch Two Melanoma Tests Based on Newly Acquired Technology | GenomeWeb

Originally published Dec. 13.

This story has been updated to include additional details from a Myriad spokesperson on the company's ongoing test development efforts in melanoma.

By Turna Ray

Myriad Genetics plans to launch a newly acquired diagnostic test for melanoma in the second half of 2011 and is planning to develop a prognostic test in melanoma linked to survival, a company spokesperson told PGx Reporter last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."